NCT Number: NCT00111722
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)
The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Female patient at least 18 years old
- Patient has menses approximately monthly
- Patient has at least a 6 month history of migraine and at least a 6 month history of menstrual migraine
Exclusion criteria
- Pregnant and/or nursing mother
- Cardiovascular disease
- Uncontrolled hypertension
Treatment and study plan
Comparator: placebo / Duration of Treatment - 1 day
DrugPrimary outcomes
-
Percentage of patients with 2 hour pain relief: 4-point headache severity scale as recorded in patient diary
Secondary outcomes
-
Percentage of patients with 24-hr sustained pain relief: headache severity between 2 and 24 hrs post dose recorded in patient diary
Sponsors and collaborators
Lead sponsor
Organon and Co
Industry
Registry information
Official study title
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg Tablets for the Treatment of Menstrual Migraine
Important dates
- Study start
- 2005
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- May 25, 2005
- Registry last updated
- Aug 14, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
NCT04530110
Brain Diseases, Central Nervous System Diseases
Aurora, Colorado, United States
View Trial DetailsLong-term Atogepant in Real-world Practice
NCT07699549
Brain Diseases, Central Nervous System Diseases
Madrid, Spain
View Trial DetailsDefault Mode Network Connectivity and Nocebo Responses in Migraine: A Functional MRI Study
NCT07720895
Brain Diseases, Central Nervous System Diseases
Athens, Greece
View Trial DetailsA Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects
NCT06158737
Brain Diseases, Central Nervous System Diseases
Beijing, Beijing Municipality, China
View Trial Details